Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, Scherrer B, Ducray PS, Buchbjerg J, Vianna E, van der Pol WL, Vuillerot C, Blaettler T, Fontoura P; Olesoxime SMA Phase 2 Study Investigators
Lancet Neurol. 2017. 16(7):513-522.
This phase 2 randomised, double-blind, placebo-controlled study was done in 22 neuromuscular care centres from 7 european country aimed to study safety and efficacy of olesoxime in patients aged 3-25 years with type 2 or type 3 SMA.
The primary outcome measure was change from baseline compared with 24 months of MFM D1+D2 scores.
Olesoxime seemed to be safe and generally well tolerated at the doses studied. Results suggested that olesoxime might maintain motor function in patients with type 2 or type 3 SMA over a period of 24 months
Keywords: Spinal Muscular atrophy, Phase 2, Safety, Olesoxime
Articles dans les revues scientifiques
Cross-sectional retrospective study of muscle function in patients with glycogen storage disease type III
Decostre V, Laforêt P, Nadaj-Pakleza A, De Antonio M, Leveugle S, Ollivier G, Canal A, Kachetel K, Petit F, Eymard B, Behin A, Wahbi K, Labrune P, Hogrel JY Neuromuscul Disord. 2016. 26(9):584-92. Cette étude vise à identifier des mesures de la fonction musculaire...
Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD)
Goselink RJ, Schreuder TH, Mul K, Voermans NC, Pelsma M, de Groot IJ, van Alfen N, Franck B, Theelen T, Lemmers RJ, Mah JK, van der Maarel SM, van Engelen BG, Erasmus CE. BMC Neurol. 2016. 17;16:138. Protocol of a population-based prospective cohort study on...
Muscle MRI Findings in Childhood/Adult Onset Pompe Disease Correlate with Muscle Function
Figueroa-Bonaparte S, Segovia S, Llauger J, Belmonte I, Pedrosa I, Alejaldre A, Mayos M, Suárez-Cuartín G, Gallardo E, Illa I, Díaz-Manera J; Spanish Pompe Study Group. PLoS One. 2016. 6;11(10):e0163493. L'objectif de l'étude est d'étudiée l'utilisation de l'IRM...
The 6-minute walk test, motor function measure and quantitative thigh muscle MRI in Becker muscular dystrophy: A cross-sectional study
Fischer D, Hafner P, Rubino D, Schmid M, Neuhaus C, Jung H, Bieri O, Haas T, Gloor M, Fischmann A, Bonati U. Neuromuscul Disord. 2016. 26(7):414-22. Etude de la corrélation entre des scores fonctionnels validés, dont la MFM, des tests chronométrés, dont le teste de...
Therapy Taping Method: Therapeutic approach in two children with Duchenne Muscular Dystrophy
Iwabe-Marchese C, Morini NJr. Br J Med Med Res. 2016. 15(3): 1-7. L'objectif de l'étude était d'évaluer l'effet d'un bandage élastique en utilisant le "Therapy Taping Method" chez 2 enfants atteints de DMD. L'échelle Mesure de la Fonction Motrice-20 (MFM-20) a été...
Natural history of LGMD2A for delineating outcome measures in clinical trials
Richard I, Hogrel JY, Stockholm D, Payan CA, Fougerousse F; Calpainopathy Study Group, Eymard B, Mignard C, Lopez de Munain A, Fardeau M, Urtizberea JA. Ann Clin Transl Neurol. 2016. 4;3(4):248-65. Etude d'observation des manifestations cliniques et de la progression...